Multiple system atrophy is a rapidly progressive neurodegenerative disease with no proven disease-modifying therapy. A 2026 review by Jeong and colleagues tracks two decades of repurposed-drug trials, with one recent positive Phase 2 result.1 Research Highlights Multiple system atrophy (MSA) is a fatal α-synuclein disorder distinct from Parkinson’s disease. It progresses faster than PD (median …
The risperidone-stroke link in dementia is one of the longest-running safety signals in geriatric psychiatry, anchoring the FDA’s 2005 black-box warning on atypical antipsychotic mortality. Popular framing reduces it to “antipsychotics cause stroke in dementia” — a true sentence that flattens a multi-axis decision. Choma’s 2025 analysis of UK primary care records is the largest …
Parkinson’s disease is the second most common neurodegenerative disorder, affecting around 10 million people worldwide. The mental-health burden is heavy: depression affects 40-50% of patients9, anxiety 30-40%, sleep disorders most patients eventually, and dementia about a third of long-duration cases. Standard treatment with levodopa controls motor symptoms but doesn’t slow the underlying neurodegeneration. The clinical …
Loneliness raises measured risk of Alzheimer’s, suicidal ideation, and completed suicide. The associations are documented; the precise magnitudes are not.
Parkinson’s disease (PD), a degenerative disorder that predominantly affects the motor system, has long been a challenging condition to manage due to its complex pathology and the limited efficacy of available treatments. However, recent research presents a beacon of hope through a novel combined therapy targeting the core of Parkinson’s disease’s neuronal degradation. This innovative …
Repetitive transcranial magnetic stimulation (rTMS) is making waves in the field of Alzheimer’s disease (AD) research, offering a glimmer of hope for enhancing cognitive functions in patients. By targeting specific brain regions, rTMS has shown promising results in modulating neural activity and improving cognitive scores. This innovative therapy, coupled with real-time monitoring through electroencephalography (EEG), …
In the quest for more effective treatments for Alzheimer’s Disease (AD), berberine, a bioactive compound derived from traditional Chinese medicine, has emerged as a promising candidate. Recent preclinical studies have showcased its potential to combat the debilitating effects of AD, with evidence pointing towards its ability to improve cognitive functions, reduce hallmark AD pathologies such …